CASI Pharmaceuticals, Inc.
NASDAQ: CASI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David A. Cory
- Employees
- 233
- Headquarters
- Beijing, United States
- IPO year
- 1996
- Market cap
- $2.3M
- Website
- https://www.casipharmaceuticals.com
Loading CASI…
Loading profile data…Frequently asked questions about CASI
What does CASI Pharmaceuticals, Inc. (CASI) do?
CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and market introduction of medical treatments and drugs across China, the United States, and globally. Its marketed product, EVOMELA, is an intravenous formulation of melphalan, utilized for conditioning prior to stem cell transplantation and as a palliative option...
Where does CASI trade?
CASI Pharmaceuticals, Inc. (CASI) trades on the NASDAQ Capital Market.
What sector is CASI in?
CASI Pharmaceuticals, Inc. (CASI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CASI Pharmaceuticals, Inc.?
David A. Cory is the chief executive officer of CASI Pharmaceuticals, Inc. (CASI).
Where is CASI Pharmaceuticals, Inc. headquartered?
CASI Pharmaceuticals, Inc. is headquartered in United States.
Does CASI pay a dividend?
CASI Pharmaceuticals, Inc. (CASI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CASI go public?
CASI Pharmaceuticals, Inc. (CASI) completed its initial public offering in 1996.